Time provides a metric for judging the long-term success of battles fought and won. More than a decade ago, the advent of protease inhibitors for human immunodeficiency virus (HIV) disease was hailed as having great promise,1 which has been borne out by experience. Hope for medications that inhibit HIV entry was realized with the recent approval of a drug that blocks the CCR5 coreceptor2 and a fusion inhibitor in 2003.3 An integrase inhibitor affecting an enzyme needed for HIV replication has now been approved.4 Each represents the first agent in new classes of HIV drugs.
Zuccotti G, Smith JM. New Weapons Needed to Fight HIVA Call for Papers. JAMA. 2007;298(21):2545. doi:10.1001/jama.298.21.2545
Customize your JAMA Network experience by selecting one or more topics from the list below.